Follicum annnouces positive human ex vivo data from preclinical diabetes studies of new class of FOL peptides
Follicum AB ("Follicum" or "the Company") today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed similar results.The Company's development of a peptide-based treatment of diabetes and its complications is proceeding according to plan. Follicum has studied the ability of peptides to induce insulin secretion in Langerhans